Effect of Genistein Intake on Some Cardiovascular Risk Factors: An Updated Systematic Review and Meta-analysis |
| |
| Institution: | 1. Department of Pharmaceutical Sciences, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran;2. Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran;3. Community Medicine Department, Isfahan University of Medical Sciences, Isfahan, Iran;1. Internal Medicine Department, Yerevan State Medical University after M. Heratsi, Yerevan, Republic of Armenia;2. Cardiology Department, Yerevan State Medical University after M. Heratsi, Yerevan, Republic of Armenia;3. Internal Medicine Department, D. Halytsky Lviv National Medical University, Lviv, Ukraine;4. School of Medicine, Iran University of Medical Sciences, Teheran, Islamic Republic of Iran;5. Isfahan Cardiovascular-Research Center, Isfahan University of Medical Science, Isfahan, Islamic Republic of Iran;6. Clinical Pharmacology and Cardio-Oncology Department and Cardio-Oncology Center, M.D. Strazhesko Institute of Cardiology, Kiev, Ukraine;7. Sapienza University of Rome, Rome, Italy;8. School of Medicine, Insubria University Varese, Lombardy, Italy;9. Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine;10. Internal Disease Propedeutics Department, Yerevan State Medical University after M. Heratsi, Yerevan, Republic of Armenia;1. Hospitalist, Department of Medicine, Baptist Memorial Hospital, Memphis, TN;2. Student, Rollins School of Public Health, Emory University, Atlanta, GA;3. Resident, Department of Internal Medicine, University of University of Kansas - Wichita program, Wichita, KS;4. Medical Student, College of Medicine, University of Tennessee Health Science Center, Memphis, TN;5. Resident, Department of Internal Medicine, Lenox Hill Hospital, New York, NY;6. Program Director, Interventional Cardiology, University of Tennessee Health Science Center, Memphis, TN;7. Associate Program Director, Cardiology Fellowship, University of Tennessee Health Science Center, Memphis, TN;8. Director, Cardiac Cath Labs, Methodist University Hospital, Memphis, TN;1. Department of Cardiovascular Ultrasound, The First Hospital of China Medical University, Shenyang, People''s Republic of China;2. Department of Cardiology, The First Hospital of China Medical University, Shenyang, People''s Republic of China;3. Department of Ultrasound, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, People''s Republic of China;1. Department of Medicine, Section of Internal Medicine, Carlo Poma Hospital, Mantova Italy;2. Department of Medicine, Section of Internal Medicine, University of Verona, Verona, Italy;3. Unit of Internal Medicine “Guido Baccelli”, Department of Biomedical Sciences and Human Oncology University of Bari, Aldo Moro Medical School, Bari, Italy;1. Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX;2. Division of Cardiology, University of Texas Medical Branch, Galveston, TX;3. UCF College of Medicine/HCA Ocala Internal Medicine, Ocala, Florida;1. Third Department of Cardiology, Silesian Center for Heart Disease, Medical University of Silesia, Zabrze, Poland;2. Department of Cardiovascular Disease Prevention, Medical University of Silesia, Bytom, Poland;3. University of Illinois at Chicago, Chicago, IL;4. Jesse Brown VA Medical Center, Chicago, IL |
| |
| Abstract: | Genistein, an isoflavone in soybean products has potential cardio-protective effects and is used also as an alternative for estrogen therapy in postmenopausal women. However, results in this regard are inconsistent and also, not all risk factors related to cardiovascular supportive effects have been meta-analyzed. We searched PubMed, Scopus, ISI Web of Science, and Google Scholar from inception up to October 2020. Random-effects meta-analysis was used for data synthesis. The search included studies with information on genistein supplementation and lipid profile triglycerides (TG), total cholesterol (TC),low-density lipoprotein (LDL-C), and high-density lipoprotein HDL-C)], systolic and diastolic blood pressure (SBP & DBP), body mass index BMI] and body weight. Pooled results of studies showed that genistein intake significantly reduced TC 95%CI: -0.49(-0.80, -0.18); P=0.002)], LDL-C 95%CI: -0.60(-1.10, -0.10); P=0.018)] and SBP 95%CI: -0.52(-0.90, -0.14); P=0.007)]. DBP, HLD-C, TG, BMI, and body weight showed no meaningful improvement. Subgroup analysis showed that LDL-C and SBP were reduced more effectively in postmenopausal women with metabolic syndrome. Genistein intake more than 6 months showed a greater effect on lowering cholesterol -0.76(-1.27, -0.24), SBP -0.39(-0.70, -0.08)] and DBP -0.40(-0.81, -0.00) and increasing TG and LDL-C. This meta-analysis provides consistent evidence that genistein intake reduces the CVD risk factors of TC, LDL-C, and SBP significantly. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
